ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 90 Publications

16 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • 3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

  • MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  NIX5eJlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoDqNlUxKG6PwrC= NXH5O5pvPzJiaB?= MYXEUXNQ M{f2SINifXOnZDC5O{UhdG:|czDv[kB3cWGkaXzpeJkhcW5iY3XscJMhfHKjboPm[YN1\WRid3n0bEBDS0x4IIPpVm5C MV[yOlY2PzJ6OB?=
KG1a NGewe|JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1zoNVAuOTBizszN NXf3cHYxOjRiaB?= MYjEUXNQ MWXJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{TsZVI3PTV{N{Gy
Kasumi-1 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX3CNJpNOC1zMDFOwG0> Ml3QNlQhcA>? NW\mc2RXTE2VTx?= NV\z[2h3UUN3ME20Mlg4KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXGyOlU2OjdzMh?=
KG1a NGC4c3dCeG:ydH;zbZMhSXO|YYm= M{DqUlAuOTBizszN MXOyOEBp MmXFSG1UVw>? M4XPZYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4[wcFI3PTV{N{Gy
Kasumi-1 MmfuRZBweHSxc3nzJGF{e2G7 M1y3T|AuOTBizszN MkHoNlQhcA>? MoTkSG1UVw>? Mlu4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlHnNlY2PTJ5MUK=
MC-3  NIX3RnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDYOU8yOC9{MDFOwG0> MlLHNlQhcA>? MmjPSG1UVw>? MmrybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGrXWpAzPjR2N{[xOS=>
HN22  M1jmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4GyR|IvPS95LkWvNlIvPSEQvF2= Mn;yNlQhcA>? M{HFdmROW09? MorDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF\BPW8zPjR2N{[xOS=>
MC-3  Mnj1RZBweHSxc3nzJGF{e2G7 MYO1M|ExNzJyIN88US=> MX[yOEBp MnnhSG1UVw>? MmS3bY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= NXnpO21MOjZ2NEe2NVU>
HN22  M3vENGFxd3C2b4Ppd{BCe3OjeR?= MYqyMlUwPy53L{KyMlUh|ryP NF7CRpgzPCCq MUXEUXNQ NUTrdVdScW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> MUCyOlQ1PzZzNR?=
MOLT-4 M{O1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWxNE02ODByIH7N MnzuO|IhcA>? NX7EPJRjTE2VTx?= MXPJR|UxRTBwMUm4JO69VQ>? MWOyOlM6OjN|Mh?=
RS4;11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixNE02ODByIH7N NIO1NpE4OiCq NFfQdVJFVVOR NHfZeIdKSzVyPUCuNFAzKM7:TR?= NWPSN5E2OjZ|OUKzN|I>
JURKAT NEPjbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XZeFExNTVyMECgcm0> NVTjeIs{PzJiaB?= NYnK[Vg6TE2VTx?= NEDZOIhKSzVyPU[2JO69VQ>? NGjRXlkzPjN7MkOzNi=>
CEM R M3rINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSxNE02ODByIH7N Mn7GO|IhcA>? MnTFSG1UVw>? MlnETWM2OD13LkSg{txO NWXtZotyOjZ|OUKzN|I>
CEM S MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjVbmNMOTBvNUCwNEBvVQ>? NV;4[oVYPzJiaB?= NU\SSld[TE2VTx?= MkXjTWM2OD1zMj6xJO69VQ>? NVjW[ldEOjZ|OUKzN|I>
MOLT-4 NW\1d4t6SXCxcITvd4l{KEG|c3H5 NH7E[3AyOC1zMECwJI5O NH22XlMzPCCq NXnPc5l2TE2VTx?= MV\jZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?= NUjvXYw1OjZ|OUKzN|I>
CEM S M2TTNWFxd3C2b4Ppd{BCe3OjeR?= MlTtNVAuOTByMDDuUS=> MoDUNlQhcA>? NX\0boFMTE2VTx?= M2L0S4NifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x NUTzWo1tOjZ|OUKzN|I>
JURKAT M4HKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OxXlExOC1zMECwJI5O Mn7ZOFghcA>? M{nQPWROW09? MlHCTWM2OD17NUZCtVkvOyCwTR?= NXTDeY1kOjZzN{KyOlk>
LOUCY MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISzS4QyODBvMUCwNEBvVQ>? M1LvTlQ5KGh? MVvEUXNQ MYXJR|UxRTN{LklCtVExNjlibl2= M2DVWFI3OTd{Mk[5
WM-115 NUfmOmNpS2WubDDWbYFjcWyrdImgRZN{[Xl? MUKxNFDDqG6P MmPIO|IhcA>? NVTyZVFZ\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= NUKyOpJpOjZzMU[3O|Y>
B16 NFjETHNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkjaNVAxyqCwTR?= MYe3NkBp M2DlNIVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi NF7G[Y4zPjFzNke3Oi=>
HL-60  MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Cd3ppPzJiaB?= NYPIR|NSUUN3MNMgQUAyOC55IH7N NYHDeFkxOjZyNEW2NFk>
MOLM-13  NU\3fYZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH20bY84OiCq M1jmR2lEPTEEoE2gNlcvQSCwTR?= NXT3fmpsOjZyNEW2NFk>
OCI-AML3 NUXnS3k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHhb|Q4OiCq MlzhTWM2OMLiPTCxPVUxKG6P NUXHR2Z2OjZyNEW2NFk>
BCWM.1 NYGzfm1zSXCxcITvd4l{KEG|c3H5 M17JOFAuOS54IN88US=> MWCyOEBp NYrXToZWcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MV2yOVg6OzJ7MB?=
MWCL-1 NWC5UWtXSXCxcITvd4l{KEG|c3H5 MWiwMVEvPiEQvF2= NYn0W3Y5OjRiaB?= M4[5ZYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUiyOVg6OzJ7MB?=
MM.1s MmfTRZBweHSxc3nzJGF{e2G7 MonWNE0yNjZizszN MYKyOEBp Ml3ObY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVSyOVg6OzJ7MB?=
HCT116 M{n6eGZ2dmO2aX;uJGF{e2G7 NXT2SXhOOy9zMDFOwG0> M4e1T|EzyqCqwrC= NIfHdmRFVVOR NI\1cJhqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36= M4fjWVI2PzF3MEK4
HCT116 BAX BAK1 DKO NXL5T|NUTnWwY4Tpc44hSXO|YYm= MljFN{8yOCEQvF2= M4PHN|EzyqCqwrC= M3q1bGROW09? M{GxXolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= MlTYNlU4OTVyMki=
HCT116 MkXoSpVv[3Srb36gRZN{[Xl? NHnkV5IyOCEQvF2= MVOxNuKhcMLi NXz3[oZrTE2VTx?= MVjpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj MlroNlU4OTVyMki=
HCT116 BAX BAK1 DKO NGnYR4hHfW6ldHnvckBCe3OjeR?= NEOwdWkyOCEQvF2= NYrpfIZxOTMEoHlCpC=> MXTEUXNQ M2HMWIlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= MkO5NlU4OTVyMki=
HCT116 MVnBeZRweGijZ4mgRZN{[Xl? NVrsfFZbOTBizszN MVuxNuKhcMLi NU\JNJBvTE2VTx?= MUPpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> M135fFI2PzF3MEK4
HCT116 BAX BAK1 DKO NY[zcWVZSXW2b4DoZYd6KEG|c3H5 NUHafFJDOTBizszN MnHVNVLDqGkEoB?= MVfEUXNQ M2jTRolv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm M37kOlI2PzF3MEK4
U937 MoqwRZBweHSxc3nzJGF{e2G7 MWWwMlEzPS1{IN88US=> NEfuNJEzPCCq M3riVYVvcGGwY3XzJGRJSS:[LUGxMYlv\HWlZXSgZZBweHSxc3nz M{CzSlI2PzF2MEK0
U937  NY\WUG9SSXCxcITvd4l{KEG|c3H5 NV7zdodlOC53IN88US=> M2\Ec|I1KGh? M{GyRoVvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCgZY5lKGOjc4Dhd4UuOyCjczD3[YxtKGG|IF7vfIEhdGW4ZXy= NIfqdFgzPTdzNECyOC=>
HL-60 AAA-Bcl-2 MV\BdI9xfG:|aYOgRZN{[Xl? MkjHNE02KM7:TR?= NV\JdZQ4PDhiaB?= NXmx[G1nUUN3ME2wMlg4KM7:bf-8kIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH7YRXQzPTdzMUS2NC=>
HL-60 EEE-Bcl-2 MnTFRZBweHSxc3nzJGF{e2G7 NEHhUVIxNTVizszN M33meVQ5KGh? MVvJR|UxRTVizszt89yNKGmwZIXj[ZMh[2WubDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NI\BVWUzPTdzMUS2NC=>
U87 NWryPYkyTnWwY4Tpc44hSXO|YYm= Mon1OVAh|ryP NGLQT|UzPCCq M{PXSpJm\HWlZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBt\X[nbIOgc4YhVU2SLUKsJG1OWC1zNDDhcoQhSmOuLUK= NYjifWRlOjV4Nke2OlM>
K562 MmHNR4VtdCCYaXHibYxqfHliQYPzZZk> M{TuV|EuOTBizszN NX7odGNiPDhiaB?= MUDEUXNQ NFXVZ21KSzVyPUK2Mlch|ryP NHK2UI4zPTV7NkW2NS=>
K562/Mcl -1-IRESBim M1G3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTlwMzFOwG0> NHnC[44zPTV|NUmwNC=>
K562/Bcl- 2-IRESBim M13EeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nKN2lEPTB;MD6zOUDPxE1? NY\aZ|NJOjV3M{W5NFA>
Jurkat MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\QWIpmUUN3ME2wMlY3KM7:TR?= M{KyXVI2PTN3OUCw
JurkatΔBak M1LkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfITWM2OD53MDFOwG0> MmrwNlU2OzV7MEC=
HL60/VCR MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\QWWlEPTB-MUCwJO69VQ>? M1XzbFI2PTN3OUCw
Kasumi-1 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEGg{txO MWKyOVU{PTlyMB?=
Kasumi-1/ABT MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLFTWM2OD1yLkWxJO69VQ>? M3[2WlI2PTN3OUCw
THP-1 NYf6S2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnqSGVKSzVyPUGuNlch|ryP MWSyOVU{PTlyMB?=
U937 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;5[oxGUUN3ME21MlI6KM7:TR?= MmHvNlU2OzV7MEC=
C1498 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDWOoNKSzVyPU[uNVMh|ryP MnHCNlU2OzV7MEC=
RPMI 8226 NX70RmpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLjTWM2OD1yLkK1JO69VQ>? Mn:5NlU2OzV7MEC=
MM.1S MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnviTWM2OD1yLkSwJO69VQ>? NH;1fZYzPTV|NUmwNC=>
NCI-H929 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW4UWZEUUN3ME2xOU4zOSEQvF2= NHrIR5IzPTV|NUmwNC=>
U266 NIO1S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7nTWM2OD1yLk[4JO69VQ>? NELJfVMzPTV|NUmwNC=>
MCF-7 M1\jXGNmdGxiVnnhZoltcXS7IFHzd4F6 MnPSOUDPxE1? MYC0PEBp NEX3XlhFVVOR Ml3O[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>? M3Xkb|I2PDB7MUK0
MCF-7 NVO0VJU{SXCxcITvd4l{KEG|c3H5 MoO5OUDPxE1? M{SwclQwOjRxNEigbC=> M1zj[WROW09? MnnqbY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC= M2\FeVI2PDB7MUK0
MCF-7 NV\wWpY3TnWwY4Tpc44hSXO|YYm= MXO1JO69VQ>? M3H0TFI1KGh? M3zUc2ROW09? MnfG[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh NX[xRmUzOjV2MEmxNlQ>
MDA-MB 231  M{\RR2Z2dmO2aX;uJGF{e2G7 NXzZeYpvPSEQvF2= MlnZNlQhcA>? NFvGSolFVVOR M2TxbYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? M4LLWlI2PDB7MUK0
ZR-75-1  MlrLSpVv[3Srb36gRZN{[Xl? M2nrWFUh|ryP M2fLblI1KGh? MorHSG1UVw>? NXO2WJE4\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi MVqyOVQxQTF{NB?=
A549 Mn;QR4VtdCCYaXHibYxqfHliQYPzZZk> NHnlVo4xNTJyIN88US=> NUnFc2ZGPzJiaB?= NHvoOmtFVVOR MlPE[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? MlPqNlU{QDh5NkK=
H1299 MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mk[xNE0zOCEQvF2= MUC3NkBp NH7JTllFVVOR NHn2OZll\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MVuyOVM5QDd4Mh?=
HO-8910 MnL4R4VtdCCYaXHibYxqfHliQYPzZZk> M3e3d|AuOjBizszN Mk\kO|IhcA>? MkfUSG1UVw>? NHzOSGpl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MUOyOVM5QDd4Mh?=
HT-29 NUXSUppoS2WubDDWbYFjcWyrdImgRZN{[Xl? M3HtO|AuOjBizszN NXu5NIE2PzJiaB?= MW\EUXNQ M{H2PYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NEPwT5czPTN6OEe2Ni=>
HCT-116 NH76W|NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFnqdXYxNTJyIN88US=> MWi3NkBp MmH1SG1UVw>? M2e0doRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NHvmVGgzPTN6OEe2Ni=>
A549 MkD5RZBweHSxc3nzJGF{e2G7 NGf0b4QzOCEQvF2= NUDVT5FPPDhiaB?= MlLNSG1UVw>? M4rJSIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu MkDXNlU{QDh5NkK=
H1299 NX\uRphtSXCxcITvd4l{KEG|c3H5 NITBR28zOCEQvF2= M1fGS|Q5KGh? NXflZ5RWTE2VTx?= NEf1UW1qdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> M3z0UlI2Ozh6N{[y
Sc-1 NGHZWolE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWfFTWRpOC5yMECxMVEh|ryP NYHIcZQ6QTZiaB?= NHT3fVRl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUiyOVM4OzVyOB?=
OcI-LY18 MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3X1OFAvODByMT2xJO69VQ>? MU[5OkBp MXzk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MViyOVM4OzVyOB?=
RL  NHHvNoRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYewMlAxODFvMTFOwG0> MXu5OkBp M1Hue4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUKyOVM4OzVyOB?=
RKO MmL0R4VtdCCYaXHibYxqfHliQYPzZZk> M3Ww[VAuOTBizszN NH;zVVczPOLCiXlCpC=> NYO4WVVrTE2VTx?= NVLl[Yd3UUN3ME9ihKkzPeLCidM1US=> NUfsbVUxOjV|MESzPFM>
Caco-2 NV\1NFlIS2WubDDWbYFjcWyrdImgRZN{[Xl? NVXRd4Z2OC1zMDFOwG0> MmGzNlTjiImqwrC= MkT5SG1UVw>? MV3JR|UxRTF7LkhihKnDvU1? MnX4NlU{ODR|OEO=
DLD1 M3XqOGNmdGxiVnnhZoltcXS7IFHzd4F6 MV6wMVExKM7:TR?= NUTsdlZLOjUkgJnoxsA> MkHxSG1UVw>? NGrtVmFKSzVyPUG4Mlc56oDLwsXN M3vjc|I2OzB2M{iz
LS411N M4foNmNmdGxiVnnhZoltcXS7IFHzd4F6 NYj6OllqOC1zMDFOwG0> MlrrNlTjiImqwrC= NXjuOmdtTE2VTx?= M3;yO2lEPTB;MUGuOFfjiIoEtV2= NW\ETFR5OjV|MESzPFM>
SW620 NVTBXIc3S2WubDDWbYFjcWyrdImgRZN{[Xl? MmTnNE0yOCEQvF2= MYSyOQKBkWkEoB?= M2PBWWROW09? MlrkTWM2OD1zMj6yOQKBkcL3TR?= NW\3cVA2OjV|MESzPFM>
HCT116 NH3Q[odE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmLjNE0yOCEQvF2= MUOyOQKBkWkEoB?= M2DSVmROW09? MXnJR|UxRTJyLkS55qCKyrWP NWr6RYdLOjV|MESzPFM>
HaCaT NHTZdopE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWGwMlEwOS9zMDFOwG0> Ml;lNlQhcA>? MXXEUXNQ M{e2[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4HIUFI2OjFyN{m1
A5-RT3 NGDzd4dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4fF[lAvOS9zL{GwJO69VQ>? NUDk[mJ{OjRiaB?= MVXEUXNQ Mnrm[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGHjPG0zPTJzMEe5OS=>
HaCaT MoT1SpVv[3Srb36gRZN{[Xl? NI\xTHgyOOLCid88US=> NXH1NmNuOjRxNEigbC=> M12wbmROW09? NYLVVG9tcW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u MmLsNlUzOTB5OUW=
A5-RT3 NGXYVFdHfW6ldHnvckBCe3OjeR?= Ml3YNVDjiIoQvF2= MY[yOE81QCCq NXHZNYV[TE2VTx?= MV3pcoR2[2W|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25? NYribZFKOjV{MUC3PVU>
A5-RT3 MYnGeY5kfGmxbjDBd5NigQ>? NH7O[pY2KM7:TR?= M1SwWFYhcA>? MmXlSG1UVw>? NH3RW5hqdmS3Y3XzJJRp\SC{ZXzlZZNmKG:oIH3peI9kcG:wZILpZYwheHKxdHXpcpMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDzeZJ3cX[jbDDpckBiKGOjc4Dhd4UucW6mZYDlcoRmdnRibXHucoVz MXeyOVIyODd7NR?=
U266 MnjmSpVv[3Srb36gRZN{[Xl? MXq1NFAwPzVyIH7N MYOyOE81QCCq MlXUSG1UVw>? MkO2[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt M3[zWFI2OjB6OEi4
RPMI8226 MoLLSpVv[3Srb36gRZN{[Xl? Mnm4OVAxNzd3MDDuUS=> M2PIU|I1NzR6IHi= Mof6SG1UVw>? MX7kc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= Ml\WNlUzODh6OEi=
MM.1S M3j2cGZ2dmO2aX;uJGF{e2G7 NIWwS402ODBxN{WwJI5O MYeyOE81QCCq MVfEUXNQ MmrG[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt MWOyOVIxQDh6OB?=
Clone A MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TRfFAvOuLCk{[wJO69VQ>? M3LGW|czKGh? MluzSG1UVw>? MlO2TWM2OD15LkWg{txO M1fkT|I2OjB6OEiy
CX-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSwMlLjiJN4MDFOwG0> Mn;IO|IhcA>? Mn\oSG1UVw>? MULJR|UxRTFwODFOwG0> MVOyOVIxQDh6Mh?=
LS174T NITZOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq1bI0xNjMkgKO2NEDPxE1? NXrBZYR5PzJiaB?= NEXsZnBFVVOR MU\JR|UxRTF6LkOg{txO NXW4TmIyOjV{MEi4PFI>
HT29 NEXiZXBCeG:ydH;zbZMhSXO|YYm= M4XQWlEwPS9zMDFOwG0> NEL0W|g1QCCq MWHjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3TXOVI2OTl{MUi4
SW480 M{jsTGFxd3C2b4Ppd{BCe3OjeR?= NGnvNlEyNzVxMUCg{txO MoX0OFghcA>? MoCyZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2TH[|I2OTl{MUi4
Colo205 NY\YeJpOSXCxcITvd4l{KEG|c3H5 NVfp[25[OS93L{GwJO69VQ>? MVS0PEBp MYrjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX:yOVE6OjF6OB?=
Caco2 NWn2O24xSXCxcITvd4l{KEG|c3H5 MVexM|UwOTBizszN MY[0PEBp MnrqZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mmi5NlUyQTJzOEi=
PCI-13 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i4clczKGh? NVzJd5lHTE2VTx?= Ml3HS2k2OD1zNTFCtUAyNjhizszN NH2xelQzPTF|OUO4Oy=>
PCI-15B M4WycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\vSnhjPzJiaB?= M{nrR2ROW09? NIjWUFlIUTVyPUGxJOKyKDRwNTFOwG0> NHKzRogzPTF|OUO4Oy=>
UM-SCC22B M2C5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jmfFczKGh? NEfTU2pFVVOR M3vS[GdKPTB;MUmgxtEhOi57IN88US=> MWiyOVE{QTN6Nx?=
UM-SCC47 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TUSVczKGh? NETqUFVFVVOR MYTHTVUxRTF7INMxJFEzNjNizszN NHG3elMzPTF|OUO4Oy=>
93-VU-147T NF7BeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DxUVczKGh? MkHqSG1UVw>? NE\OUIRIUTVyPUSuN{DDuSB|LkWg{txO NE\H[mczPTF|OUO4Oy=>
UD-SCC2 NFrGTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH33Z3o4OiCq M4P4VmROW09? M4[1eWdKPTB;MkigxtEhOi57IN88US=> Mmr2NlUyOzl|OEe=
UPCI:SCC90 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO1bZd4PzJiaB?= NEXDUIdFVVOR M1LRVmdKPTB;Nj62JOKyKDFwNTFOwG0> M1nWU|I2OTN7M{i3
RPMI-8226  NVvNPI5tS2WubDDWbYFjcWyrdImgRZN{[Xl? NEDVdW4yOjVxMkWwM|UxOCCwTR?= M36zeVQ5cMLi NHP2cnJFVVOR MVHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHfGZ4gzPTByOEKwNi=>
OPM-2  MojVR4VtdCCYaXHibYxqfHliQYPzZZk> NWTTXno6OTJ3L{K1NE82ODBibl2= NFrw[pI1QGkEoB?= MkfzSG1UVw>? Ml74[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYSyOVAxQDJyMh?=
RPMI-8226  MnLURZBweHSxc3nzJGF{e2G7 M4LpWVEzPS9{NUCvOVAxKG6P M13DR|Q5cMLi NIXJSplFVVOR NH3JNodqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXTldppiOjVyMEiyNFI>
OPM-2  MorCRZBweHSxc3nzJGF{e2G7 NGjyOIkyOjVxMkWwM|UxOCCwTR?= MnT2OFhpyqB? NGGzOJBFVVOR MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWqyOVAxQDJyMh?=
COG-LL-319 MWLGeY5kfGmxbjDBd5NigQ>? MnriNVAxKG6P MkXDNU8{NzZiaB?= MnTKSG1UVw>? MneybY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? NUiwWINLOjR7NUG0O|I>
RS4;11 NUnFNFRuTnWwY4Tpc44hSXO|YYm= NXv2O|JXOTByIH7N MnHqNU8{NzZiaB?= NXXpfWFPTE2VTx?= Mm\5bY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? NGqy[oszPDl3MUS3Ni=>

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% Propylene glycol, 5% Tween 80, 65% D5W
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID